Introduction: Cancer has long been considered a genetic disease characterized by a myriad of mutations that drive cancer progression. Recent accumulating evidence indicates that the dysregulated metabolism in cancer cells is more than a hallmark of cancer but may be the underlying cause of the tumor.In the clinical management of cancer with personalized medicine will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence,... This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease. Therefore, the purpose of this study is to investigate new methods of cancer care based on personalized medicine.
Methods: In this article, a collection of articles dealing with the topic of the proposed cancer care based on personalized medicine from pubmed, google scholar, nature databases with the keywords Personalized medicine, Cancer management, Patient-derived organoids, Breast cancer, Cancer care , Ovarian cancer, Lung cancer,… were searched and finally 150 articles related to the subject were found and analyzed.
Results: The results of the studies showed:
Three-dimensional (3D) modelling systems, from cell lines to organoid or tumoroid cultures, represent enhanced starting points from which improved translational outcomes for women with ovarian cancer will emerge. Consideration of molecular testing for a driver mutation is imperative for all providers caring for patients with a new suspected lung cancer diagnosis, as discovery of an actionable mutation will have dramatic implications in regards to patient survival and quality of life. Tumor genomic profiling is the standard of care for breast cancer that could contribute to taking steps to better management of malignancies. Circulating tumor DNA (ctDNA), accurately described by the term liquid profiling (LP), enables real-time assessment of the tumor mutational profile as a minimally invasive test and has therefore rapidly gained traction, particular for the management of cancer patients. Also Given the potential for cancer organoids to accurately recapitulate the intra- and intertumoral biological heterogeneity associated with patient-specific cancers, eliminating the undesirable technical variability accompanying cancer organoid culture is necessary to establish reproducible platforms that accelerate translatable insights into patient care. researchers are digging into personalized medicine for the management of chemotolerance to increase cancer survivors with better quality of life. Recently, various genes/polymorphisms have been explored to be used as predictors of drug response and severity of cancer-linked symptoms.
Conclusion: According to the results of the studies and the impact of personalized medicine in the care of cancer patients according to the patient's family tree, Three-dimensional (3D) modeling systems, molecular testing, Tumor genomic profiling,... led us to identify the optimal dose of the Personalized drug and find relevant molecular targets that can help in disease management and introduction of effective treatments.
Keywords: Cancer care , Personalized medicine , Organoid , Tumor